Fuertes, Melody A.
HRN: 22-59-91 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/14/2025
CEFTAZIDIME 1GM (VIAL)
01/14/2025
01/21/2025
IVTT
2g
Q8
Dm Foot With Gangrene
Waiting Final Action
Indication: Empiric Type of Infection: Bone & JointSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes